# Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

> **NCT01406418** · PHASE1 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 64 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CR6261 2 mg/kg
- **BIOLOGICAL:** CR6261 5 mg/kg
- **BIOLOGICAL:** CR6261 15 mg/kg
- **BIOLOGICAL:** CR6261 30 mg/kg
- **BIOLOGICAL:** CR6261 50 mg/kg
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01406418
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406418, "Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01406418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*